Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive. The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market. The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone. Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.
The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period. In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally. Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.
In 2019, the market size of Combined hormonal contraceptive is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Combined hormonal contraceptive.
This report studies the global market size of Combined hormonal contraceptive, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Combined hormonal contraceptive sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Johnson & Johnson
Market Segment by Product Type
Market Segment by Application
Key Regions split in this report: breakdown data for each region.
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Combined hormonal contraceptive status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Combined hormonal contraceptive manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Combined hormonal contraceptive are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025